248 related articles for article (PubMed ID: 9469413)
1. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production.
Siemasko K; Chong AS; Jäck HM; Gong H; Williams JW; Finnegan A
J Immunol; 1998 Feb; 160(4):1581-8. PubMed ID: 9469413
[TBL] [Abstract][Full Text] [Related]
2. TGF-beta inhibits IL-12-induced activation of Jak-STAT pathway in T lymphocytes.
Bright JJ; Sriram S
J Immunol; 1998 Aug; 161(4):1772-7. PubMed ID: 9712043
[TBL] [Abstract][Full Text] [Related]
3. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response.
Wang LH; Kirken RA; Erwin RA; Yu CR; Farrar WL
J Immunol; 1999 Apr; 162(7):3897-904. PubMed ID: 10201908
[TBL] [Abstract][Full Text] [Related]
4. Differential regulation of the Janus kinase-STAT pathway and biologic function of IL-13 in primary human NK and T cells: a comparative study with IL-4.
Yu CR; Kirken RA; Malabarba MG; Young HA; Ortaldo JR
J Immunol; 1998 Jul; 161(1):218-27. PubMed ID: 9647227
[TBL] [Abstract][Full Text] [Related]
5. STAT6 is required for IL-4-induced germline Ig gene transcription and switch recombination.
Linehan LA; Warren WD; Thompson PA; Grusby MJ; Berton MT
J Immunol; 1998 Jul; 161(1):302-10. PubMed ID: 9647237
[TBL] [Abstract][Full Text] [Related]
6. Cholera toxin acts synergistically with IL-4 to promote IgG1 switch differentiation.
Lycke N; Severinson E; Strober W
J Immunol; 1990 Nov; 145(10):3316-24. PubMed ID: 1700007
[TBL] [Abstract][Full Text] [Related]
7. Phytochemical inhibition of interleukin-4-activated Stat6 and expression of VCAM-1.
Schnyder B; Schnyder-Candrian S; Panski A; Bömmel H; Heim M; Duschl A; Moser R
Biochem Biophys Res Commun; 2002 Apr; 292(4):841-7. PubMed ID: 11944890
[TBL] [Abstract][Full Text] [Related]
8. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion.
Korn T; Magnus T; Toyka K; Jung S
J Leukoc Biol; 2004 Nov; 76(5):950-60. PubMed ID: 15328336
[TBL] [Abstract][Full Text] [Related]
9. Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells.
Kirken RA; Erwin RA; Wang L; Wang Y; Rui H; Farrar WL
J Immunol; 2000 Nov; 165(9):5097-104. PubMed ID: 11046040
[TBL] [Abstract][Full Text] [Related]
10. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
Cherwinski HM; Cohn RG; Cheung P; Webster DJ; Xu YZ; Caulfield JP; Young JM; Nakano G; Ransom JT
J Pharmacol Exp Ther; 1995 Nov; 275(2):1043-9. PubMed ID: 7473131
[TBL] [Abstract][Full Text] [Related]
11. Antigen-receptor engagement in B cells induces nuclear expression of STAT5 and STAT6 proteins that bind and transactivate an IFN-gamma activation site.
Karras JG; Wang Z; Coniglio SJ; Frank DA; Rothstein TL
J Immunol; 1996 Jul; 157(1):39-47. PubMed ID: 8683142
[TBL] [Abstract][Full Text] [Related]
12. IL-4 inhibits the production of TNF-alpha and IL-12 by STAT6-dependent and -independent mechanisms.
Levings MK; Schrader JW
J Immunol; 1999 May; 162(9):5224-9. PubMed ID: 10227996
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-4-induced transcriptional activation by stat6 involves multiple serine/threonine kinase pathways and serine phosphorylation of stat6.
Pesu M; Takaluoma K; Aittomäki S; Lagerstedt A; Saksela K; Kovanen PE; Silvennoinen O
Blood; 2000 Jan; 95(2):494-502. PubMed ID: 10627454
[TBL] [Abstract][Full Text] [Related]
14. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism.
Cherwinski HM; McCarley D; Schatzman R; Devens B; Ransom JT
J Pharmacol Exp Ther; 1995 Jan; 272(1):460-8. PubMed ID: 7529314
[TBL] [Abstract][Full Text] [Related]
15. IL-3 and IL-4 activate cyclic nucleotide phosphodiesterases 3 (PDE3) and 4 (PDE4) by different mechanisms in FDCP2 myeloid cells.
Ahmad F; Gao G; Wang LM; Landstrom TR; Degerman E; Pierce JH; Manganiello VC
J Immunol; 1999 Apr; 162(8):4864-75. PubMed ID: 10202031
[TBL] [Abstract][Full Text] [Related]
16. CD40-mediated regulation of interleukin-4 signaling pathways in B lymphocytes.
Siepmann K; Wohlleben G; Gray D
Eur J Immunol; 1996 Jul; 26(7):1544-52. PubMed ID: 8766559
[TBL] [Abstract][Full Text] [Related]
17. Isotype switching in anti-immunoglobulin-activated B lymphoblasts: differential requirements for interleukin 4 and other lymphokines to elicit membrane vs. secreted IgG1.
Purkerson JM; Isakson PC
Eur J Immunol; 1991 Mar; 21(3):707-14. PubMed ID: 2009912
[TBL] [Abstract][Full Text] [Related]
18. Cholera toxin promotes B cell isotype switching by two different mechanisms. cAMP induction augments germ-line Ig H-chain RNA transcripts whereas membrane ganglioside GM1-receptor binding enhances later events in differentiation.
Lycke NY
J Immunol; 1993 Jun; 150(11):4810-21. PubMed ID: 8388421
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-4 mediates STAT6 activation in 3T3-L1 preadipocytes but not adipocytes.
Deng J; Hua K; Lesser SS; Greiner AH; Walter AW; Marrero MB; Harp JB
Biochem Biophys Res Commun; 2000 Jan; 267(2):516-20. PubMed ID: 10631093
[TBL] [Abstract][Full Text] [Related]
20. Tyrphostin B42 inhibits IL-12-induced tyrosine phosphorylation and activation of Janus kinase-2 and prevents experimental allergic encephalomyelitis.
Bright JJ; Du C; Sriram S
J Immunol; 1999 May; 162(10):6255-62. PubMed ID: 10229872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
